LCT 0.01
Choroid plexus tissue shipped to Sydney as NTCELL research advances
Living Cell Technologies has advanced its Parkinson’s disease research, with choroid plexus tissue successfully shipped from New Zealand to Australia as part of the third clinical trial of NTCELL.
Quarterly Activity Report and Appendix 4C
LCT's Activity and Cashflow (Appendix 4C) report for the June quarter 2022, highlighted by the move to apply the benefits of artificial intelligence towards the Company’s third clinical trial of NTCELL in Parkinson’s disease.
Change of Director's Interest Notice - B Tuch and A Kelly
Change of Director's Interest Notice for LCT Directors, Professor Bernie Tuch and Dr Andrew Kelly.
Ceasing to be a substantial holder
Notice of ceasing to be a substantial holder.
Investor Presentation - Gold Coast Investment Showcase
Living Cell Technologies' Chief Operating Officer, Dr Belinda Di Bartolo, presented an update on LCT's third clinical trial of NTCELL in Parkinson's disease at the Gold Coast Investment Showcase conference.